stock solution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
Practical handling often includes dividing a reconstituted solution into single-use aliquots to limit freeze-thaw cycling. Vials made of low-binding plastic or glass with inert closures are common, and some protocols add a carrier protein or bulking agent to reduce adsorption. Filtration through a sterile filter may be used when a sterile solution is required, but filters can retain peptide if binding occurs. Mixing is usually gentle; vigorous vortexing can introduce air-liquid interfaces that promote aggregation. Each of these steps involves trade-offs between sterility, recovery, and analytical accuracy.
Storage recommendations for reconstituted peptides vary by sequence and intended use, so general rules remain broad. A common laboratory practice is to keep solutions cold, sometimes frozen, and protected from light, but freezing itself can damage certain peptides. The pH of the solution may be adjusted to a range where the peptide is most stable, though changing pH can also alter solubility. Documentation of reconstitution date, solvent, concentration, and storage conditions supports reproducibility. Stability data for a specific peptide are generally established by direct measurement rather than assumed from related compounds.
Once a peptide is in solution, its stability depends on temperature, pH, ionic strength, and the presence of oxygen or light. Many peptides are less stable in liquid form than as dry powders because hydrolysis, oxidation, and aggregation can proceed faster in water. Storage at low temperature slows these reactions but does not eliminate them. Some sequences are particularly sensitive to repeated freezing and thawing, which can cause precipitation or conformational changes. The container material and headspace also influence adsorption and surface-induced aggregation.
Reconstitution is the process of adding a liquid to a lyophilized peptide so that the dried material dissolves into solution. Lyophilization removes water from a frozen peptide preparation under reduced pressure, leaving a porous solid or powder. The dried form often has greater long-term stability than a liquid because hydrolysis and oxidation are slowed. In laboratory work, reconstitution is usually the first step before dilution, analysis, or further experiments. The result is a stock solution whose concentration depends on the volume of solvent added and the amount of peptide in the vial.
Solvent choice depends on the peptide's sequence, charge, and solubility profile. Sterile water is common for freely soluble peptides, while aqueous buffers or dilute acid or base may be needed for others. Some sequences contain hydrophobic regions that resist water alone and require a small amount of organic co-solvent. The solvent's pH can affect charge state, aggregation, and stability. Because peptides vary widely, no single universal reconstitution liquid exists, and suppliers often provide a recommended solvent based on testing of a specific lot or sequence.
After a solvent is added, the vial is typically swirled or gently inverted rather than shaken vigorously. Shaking can introduce air and shear forces that promote foaming or aggregation, especially for longer peptides. Dissolution may take several minutes, and the solution should become clear unless the peptide is intentionally in suspension. Concentration is calculated from the mass of peptide stated on the vial label divided by the total liquid volume. If the dried peptide contains salts or counterions, the actual peptide content may be lower than the nominal mass.
| Property | Value | Notes |
|---|---|---|
| Solution appearance | Clear to slightly opalescent | Cloudiness can signal aggregation or undissolved material. |
| Typical short-term storage | 2-8 °C | Refrigeration is common for solutions used within a short period. |
| Typical long-term storage | -20 °C or lower | Freezing may require aliquoting to avoid repeated freeze-thaw cycles. |
| Common container | Low-binding plastic or glass vial | Low-binding surfaces can reduce adsorptive loss. |
| Common preservative | Bacteriostatic water | Contains an antimicrobial agent; not compatible with all analytical workflows. |
After a dried peptide is dissolved, the resulting solution is treated as a distinct material with its own stability profile. Temperature, pH, ionic strength, and peptide concentration all influence how long the solution remains suitable for its intended laboratory use. Some sequences are prone to oxidation, deamidation, or aggregation. Because these processes vary widely, no single storage condition applies to every peptide. Buffer composition and light exposure can also shift degradation rates.
Aseptic technique matters when the solution will contact cells or biological reagents. Working in a clean environment, using sterile liquids and containers, and minimizing open-vial time reduce the chance of microbial contamination. Filtration through a sterile filter can remove particles and microorganisms, but some filters adsorb peptides and some peptides are retained by certain membrane materials. Compatibility between the peptide, solvent, and filter should be checked when recovery is critical.
Quality verification after reconstitution may include visual inspection, pH measurement, and chromatographic analysis. Reverse-phase high-performance liquid chromatography can reveal degradation peaks, while mass spectrometry can confirm molecular identity. Concentration may be estimated from the weighed peptide mass or determined by amino acid analysis, UV absorbance, or quantitative chromatography. Documentation of solvent, volume, date, and storage conditions supports traceability and reproducibility. Records also help identify when a solution was prepared and whether it has exceeded an established in-house shelf life.
Cold storage slows most degradation but does not stop it. Reconstituted solutions are commonly divided into aliquots and held at -20 °C or -80 °C, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or precipitation, so single-use aliquots are preferred. Some peptides tolerate refrigeration for short intervals, while others require freezing immediately. Light-sensitive residues may need amber or foil-wrapped containers. The optimal condition remains peptide-specific and should be supported by stability data.
Analytical checks can detect changes in a reconstituted stock over time. Reverse-phase high-performance liquid chromatography can show loss of main peak, new impurity peaks, or altered retention. Mass spectrometry confirms molecular identity and can reveal modifications. Visual inspection for particles, color change, or turbidity provides a simple first check. If a solution shows signs of degradation or contamination, it is typically discarded rather than re-purified in a routine laboratory.
After a peptide is reconstituted, analytical checks can confirm identity, concentration, and purity. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry provides a mass value that supports sequence identity, while ultraviolet absorbance at 214 or 280 nanometers is often used for concentration estimation when the extinction coefficient is known. These methods answer different questions and are complementary. A single measurement rarely establishes full quality, because the same sample can appear acceptable by one method and fail another.
Concentration calculations depend on the amount of peptide present in the vial and the volume of solvent added. Lyophilized preparations often contain counterions, salts, or residual water, so the labeled mass may not equal the mass of the peptide itself. This difference can produce a calculated concentration that is higher than the true peptide concentration. Analytical determination of peptide content, rather than reliance on the vial label alone, reduces this source of error. Uncertainty in volume measurement also contributes, especially when small liquid volumes are handled.
Quality records typically include a certificate of analysis, batch number, molecular weight, purity result, and recommended storage conditions. After reconstitution, a laboratory log may record solvent, final volume, date, and storage location. Such documentation supports reproducibility and allows later investigation if a preparation behaves unexpectedly. Stability studies often examine purity and concentration over time under defined temperatures, but results are not universally transferable between peptides or formulations. Open questions remain about how best to predict aggregation for specific sequences and how much analytical testing is sufficient for routine laboratory work.
Mayer B. Davidson is an American physician and author who is an expert on diabetes and the algorithmic dosing of insulin. A Professor of Medicine at both the Charles R. Drew University of Medicine and Science and the David Geffen School of Medicine at UCLA, Davidson has studied algorithmic dosing of insulin as a means of controlling diabetes in insulin-using patients.
Protein S aids this process by catalysing the proteolysis at Arg306, in which the A2 domain of Factor V is dissociated from the rest of the protein. Protein S also binds to Factor Xa, inhibiting the latter from diminishing APC's inactivation of Factor Va. The inactivation of Factor VIIIa is not as well understood. The half-life of Factor VIIIa is only around two minutes unless Factor IXa is present to stabilise it. Some have questioned the significance of APC's inactivation of Factor VIIIa, and it is unknown to what degree Factor V and protein S are cofactors in its proteolysis. It is known that APC works on Factor VIIIa by cleaving at two sites, Arg336 and Arg562, either of which is sufficient to disable Factor VIIIa and convert it to Factor VIIIi.
The condition is transmitted as an autosomal recessive trait, and often affects children of consanguineous parents. The physical findings and symptoms vary greatly among each individual. Genetic diseases are determined by two genes, one from the mother and one from the father. Recessive genetic disorders occur when an individual inherits the same abnormal gene for the same trait from each parent. If one of the inherited genes is normal, while the other is for the disease, the person will only be a carrier and will not display any symptoms. The risk for two carrier parents to both pass the defective gene and, therefore, have an affected child is 25 percent with each pregnancy. The risk to have a child who is a carrier like the parents is 50 percent with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25 percent. Researchers have determined that the Rabson–Mendenhall syndrome is caused by mutations of the insulin receptor gene. The insulin receptor gene is located on the short arm (p) of chromosome 19. Mutations of the insulin-receptor gene lead to an alteration of structure or reduced number of insulin receptors. This results in reduced binding of insulin, and may also lead to abnormalities in the post-receptor pathway. Individuals with Rabson-Mendenall syndrome will need ways to compensate for their insulin resistance, and may do this by increasing insulin secretion.
Sources: en.wikipedia.org
== Contraindications == Due to its effects on blood pressure (generally a transient increase in systolic blood pressure by 6 mmHg, and diastolic blood pressure by 3 mmHg), bremelanotide is considered contraindicated in people with uncontrolled high blood pressure or cardiovascular disease. As long as bremelanotide is not used more than once in one day, it is not expected to cause more severe increases in blood pressure.
== Outcomes == Outcomes of muscle atrophy depend on the underlying cause and the health of the patient. Immobility or bed rest in populations predisposed to muscle atrophy, such as the elderly or those with disease states that commonly cause cachexia, can cause dramatic muscle atrophy and impact on functional outcomes. In the elderly, this often leads to decreased biological reserve and increased vulnerability to stressors known as the "frailty syndrome." Loss of lean body mass is also associated with increased risk of infection, decreased immunity, and poor wound healing. The weakness that accompanies muscle atrophy leads to higher risk of falls, fractures, physical disability, need for institutional care, reduced quality of life, increased mortality, and increased healthcare costs.
2) Order 1993 (S.I. 1993/2788) County Court Appeals (Amendment) (Transitional Provisions) Order 1993 (S.I. 1993/2789) Transport Act 1985 (Modifications in Schedule 4 to the Transport Act 1968) (Further Modification) Order 1993 (S.I. 1993/2797) Sex Discrimination and Equal Pay (Remedies) Regulations 1993 (S.I. 1993/2798) Home Energy Efficiency Grants (Amendment) Regulations 1993 (S.I. 1993/2799)
Sources: en.wikipedia.org
The Appalachian Uplands are one of the seven physiographic divisions in Canada. Canada's GSC does not use the same classification system as the USGS below the division level. The agency does break the divisions of the Appalachian Uplands into 13 subsections that are in four different political provinces of Canada.
== Road traffic death rate == The World Health Organization's (WHO) Global Status Report on Road Safety 2018 reported Thailand as having the world's sixth highest "estimated road traffic death rate per 100,000 population" (2016 figures). Four of the top death rates occur in African nations. They, and the Dominican Republic, are the only countries to exceed Thailand's death rate. Among ASEAN nations, Thailand was ranked one, with 32.7 deaths per 100,000 persons; Vietnam, 26.4; Malaysia, 23.6; Myanmar, 19.9; Cambodia, 17.8; Laos, 16.6; Philippines, 12.3; Indonesia, 12.2; Singapore, 2.8. Global Status Report on Road Safety 2015: Thailand has an "Estimated Road Traffic Death Rate" of 36.2 persons per 100,000 population, ranked 2 of 180 countries (1: worst, 180: best). Seventy-three percent of fatalities involved two- or three-wheeled motorized vehicles. In other ASEAN countries, corresponding death rates were: Vietnam, 24.5; Malaysia, 24; Myanmar, 20.3; Cambodia, 17.4; Indonesia, 15.3; Laos, 14.3; Philippines, 10.5; Singapore, 3.6.
=== North America === In North America, medical physics training is offered at the master's, doctorate, post-doctorate and/or residency levels. A professional doctorate has also been recently introduced as an option. Several universities in Canada and the United States offer these degrees. As of October 2013, over 70 universities in North America have medical physics graduate programs or residencies that are accredited by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP). The majority of residencies are therapy, but diagnostic and nuclear have also been on the rise in the past several years. In the United States, professional certification is obtained from the American Board of Radiology (for all 4 areas) the American Board of Medical Physics (for MRI), the American Board of Science in Nuclear Medicine (for Nuc Med and PET). As of 2012, enrollment in a CAMPEP-accredited residency or graduate program is required to start the ABR certification process. As of 2013, completion of a CAMPEP-accredited residency is required to advance to part 2 of the ABR certification process. In Canada, professional certification is obtained from the Canadian College of Physicists in Medicine (for all 4 areas and Mammography). Since 2016, eligibility requirements for Radiation Oncology Physics certification includes graduation and post-graduate training from a CAMPEP accredited institution.
== History == In 1912 Max Von Laue directed X-rays at crystallized copper sulfate generating a diffraction pattern. These experiments led to the development of X-ray crystallography, and its usage in exploring biological structures. In 1951, Rosalind Franklin and Maurice Wilkins used X-ray diffraction patterns to capture the first image of deoxyribonucleic acid (DNA). Francis Crick and James Watson modeled the double helical structure of DNA using this same technique in 1953 and received the Nobel Prize in Medicine along with Wilkins in 1962. Pepsin crystals were the first proteins to be crystallized for use in X-ray diffraction, by Theodore Svedberg who received the 1962 Nobel Prize in Chemistry. The first tertiary protein structure, that of myoglobin, was published in 1958 by John Kendrew. During this time, modeling of protein structures was done using balsa wood or wire models. With the invention of modeling software such as CCP4 in the late 1970s, modeling is now done with computer assistance. Recent developments in the field have included the generation of X-ray free electron lasers, allowing analysis of the dynamics and motion of biological molecules, and the use of structural biology in assisting synthetic biology. In the late 1930s and early 1940s, the combination of work done by Isidor Rabi, Felix Bloch, and Edward Mills Purcell led to the development of nuclear magnetic resonance (NMR). Currently, solid-state NMR is widely used in the field of structural biology to determine the structure and dynamic nature of proteins (protein NMR).
Sources: en.wikipedia.org
Storage time depends on peptide sequence, concentration, solvent, and temperature. No single shelf life applies to all peptides. Stability should be determined by analytical testing for the specific preparation.
Aliquots limit the number of freeze-thaw cycles a solution undergoes. Repeated temperature changes can cause aggregation, precipitation, or loss of peptide to container surfaces. Single-use portions also reduce contamination risk when handled aseptically.
Some amino acid side chains, such as tryptophan and tyrosine, can undergo photo-oxidation. Amber vials or foil wrapping are used to reduce light exposure in laboratory settings. The sensitivity varies widely among peptides.
Reconstitution means adding a liquid to a dried peptide to form a solution. The dried material is usually a lyophilized powder or cake produced by freeze-drying. The resulting liquid is a stock solution that can be diluted or analyzed further.